…eding. Obstruction of the cystic duct by FCSEMS may precipitate acute cholecystitis; however, the incidence of this complication is not well define…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 80 of 2459…cted in increased intestinal permeability, is often reported in irritable bowel syndrome (IBS), particularly in diarrhoea-predominant and post-infective…
… untreated lesion per RECIST v1.1, Child–Pugh score 5 or 6, and ECOG performance status 0 or 1 were included. Pts were randomized 1:1 to receive NIVO 1…
…ue to the long-term complications including liver cirrhosis and hepatocellular carcinoma. Accordingly, it is imperative to evaluate the temporal trends …
… findings highlight the need for combination therapies, such as bempedoic acid, to optimize lipid management and achieve NICE targets in prima…
…I) for all-cause mortality were significant for each biomarker: NT-proBNP 1.35 (1.26-1.44); hs-cTnT 1.75 (1.48-2.07); hs-cTnI 1.33 (1.24-…
…rdiovascular events (MACE). Anti-inflammatory therapies such as colchicine and canakinumab have reduced MACE in chronic coronary syndromes…
…Introduction Cardiac sarcoidosis can lead to complications such as advanced heart failure, high-…
…utcome of the proportion of referrals proceeding to TAVI at the Heart Valve Centre was analysed.Results Mean±SD time from referral to TAVI was sig…
…14, p=0.620). Multivariable regression models demonstrated that pCVD patients had significantly lower odds of device infection (aOR …
…ing, ventilation inhomogeneity and increased airway-resistance. Airway disease is prevalent in rheumatic diseases like rheumatoid arthritis an…